Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 55Neoplasms 15Sarcoma 12Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Ovarian Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Liposarcoma 2Leiomyosarcoma 2Carcinoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lymphoma 1

Interventions

Cetuximab 11Cisplatin 10Radiotherapy 8Docetaxel 8Erlotinib Hydrochloride 7Paclitaxel 6Gemcitabine 6Chemotherapy, Adjuvant 6Immunohistochemistry 5Sorafenib 4Radiosurgery 4Carboplatin 4Capecitabine 4Biopsy 4sargramostim 3Vorinostat 3Trastuzumab 3Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3Filgrastim 3Doxorubicin 3Bevacizumab 3ixabepilone 2aldesleukin 2Taxes 2SS1(dsFv)PE38 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Salivary Gland Neoplasms × eribulin × Clear all
NCT01613768 2018-09-28

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

University of Washington

Phase 2 Completed
29 enrolled 12 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡